Godwin S J, Tortelli C F, Parkin M L, Head G A
Neuropharmacology Laboratory, Baker Medical Research Institute, Melbourne, Victoria, Australia.
J Auton Nerv Syst. 1998 Oct 15;72(2-3):195-204. doi: 10.1016/s0165-1838(98)00105-2.
In 10 conscious rabbits, the baroreceptor-heart rate (HR) reflex effects of centrally acting antihypertensive agents with high affinity for imidazoline receptors (IRs), moxonidine and rilmenidine, were compared with clonidine which acts predominantly via central alpha2-adrenoceptors. Dose regimens were chosen to give similar hypotension (-17+/-1 mm Hg) and bradycardia (-27+/-2 b/min) for all three agents given into the fourth ventricle. Baroreceptor-HR reflex curves were assessed by i.v. drug induced changes in blood pressure. With all treatments, the baroreflex curves with both vagal and sympathetic effectors intact were shifted to the left, corresponding to the hypotension, and the bradycardia plateau was reduced. Rilmenidine and moxonidine also reduced the upper plateau such that the curves were shifted parallel down the HR scale with no change in the HR range. By contrast, clonidine only decreased the lower plateau, and thus increased HR range (+19+/-6%). Moxonidine, but not rilmenidine, reduced the baroreflex gain by reducing the curvature. Clonidine also decreased curvature but this did not result in a reduction in gain as it was offset by the increase in HR range. The gain and range of the cardiac sympathetic component, as assessed after vagal blockade, was reduced by rilmenidine by 53 and 40% respectively, but was not affected by the other agents. The calculated vagal component of the curves showed that all agents produced a greater vagal bradycardia in response to a rise in pressure and that both rilmenidine and clonidine increased vagal HR range. The present study results show that many of the baroreflex effects of clonidine, such as facilitating cardiac vagal responses, are shared by the second generation agent rilmenidine, suggesting that they are primarily due to alpha2-adrenoceptor activation. In addition, the inhibition of the sympathetic component of the baroreflex, observed with rilmenidine, and not clonidine suggests that this effect may involve IRs. By contrast moxonidine, the most specific agent for I1 receptors, produces mainly a baroreflex independent inhibition of cardiac sympathetic activity with little effect on vagal activity.
在10只清醒的兔子中,将对咪唑啉受体(IRs)具有高亲和力的中枢性抗高血压药物莫索尼定和利美尼定与主要通过中枢α2-肾上腺素能受体起作用的可乐定的压力感受器-心率(HR)反射效应进行了比较。选择给药方案以使三种药物注入第四脑室后产生相似的低血压(-17±1 mmHg)和心动过缓(-27±2次/分钟)。通过静脉注射药物引起的血压变化来评估压力感受器-HR反射曲线。在所有治疗中,迷走神经和交感神经效应器均完整的压力反射曲线向左移动,与低血压相对应,并且心动过缓平台降低。利美尼定和莫索尼定还降低了上平台,使得曲线在HR尺度上平行下移,HR范围无变化。相比之下,可乐定仅降低了下平台,从而增加了HR范围(+19±6%)。莫索尼定而非利美尼定通过减小曲率降低了压力反射增益。可乐定也降低了曲率,但这并未导致增益降低,因为它被HR范围的增加所抵消。在迷走神经阻断后评估的心脏交感神经成分的增益和范围,利美尼定分别降低了53%和40%,但其他药物未对其产生影响。曲线的计算迷走神经成分表明,所有药物在压力升高时均产生更大的迷走神经心动过缓,并且利美尼定和可乐定均增加了迷走神经HR范围。本研究结果表明,可乐定的许多压力反射效应,如促进心脏迷走神经反应,第二代药物利美尼定也具有,这表明它们主要是由于α2-肾上腺素能受体激活所致。此外,利美尼定而非可乐定观察到的压力反射交感神经成分的抑制表明,这种效应可能涉及IRs。相比之下,对I1受体最具特异性的药物莫索尼定主要产生压力反射非依赖性的心脏交感神经活动抑制,对迷走神经活动影响很小。